106 related articles for article (PubMed ID: 1977861)
1. Enhanced natural killer cell activity in patients with cervical carcinoma by postoperative PS-K immunotherapy.
Chou CY; Hsieh CY; Chen CA; Hsieh KH
J Formos Med Assoc; 1990 Jun; 89(6):461-5. PubMed ID: 1977861
[TBL] [Abstract][Full Text] [Related]
2. Decreased natural killer cell activity in patients with invasive cervical carcinoma.
Chou CY; Hsieh CY; Hsieh KH; Chen CA
Taiwan Yi Xue Hui Za Zhi; 1989 Feb; 88(2):128-31. PubMed ID: 2788713
[TBL] [Abstract][Full Text] [Related]
3. [A case of uterine cervical carcinoma showing an interesting clinical course with PS-K after radiotherapy].
Okazaki A; Mitsuhashi N; Yamakawa M; Nozaki M; Takeuchi M; Niibe H
Rinsho Hoshasen; 1986 May; 31(5):659-62. PubMed ID: 3747223
[No Abstract] [Full Text] [Related]
4. NK cell activity in the presence of IL-12 is a prognostic assay to neoadjuvant chemotherapy in cervical cancer.
Cosiski Marana HR; Santana da Silva J; Moreira de Andrade J
Gynecol Oncol; 2000 Sep; 78(3 Pt 1):318-23. PubMed ID: 10985887
[TBL] [Abstract][Full Text] [Related]
5. [Studies on the influence of interleukin 2 (IL-2) on antitumor effector mechanisms in patients with cervical cancer].
Yamamoto K
Nihon Sanka Fujinka Gakkai Zasshi; 1986 Dec; 38(12):2251-8. PubMed ID: 3492578
[TBL] [Abstract][Full Text] [Related]
6. Natural killer cells and interleukin-12 in patients with advanced cervical cancer under neoadjuvant chemotherapy.
Marana HR; Andrade JM; Silva JS
Braz J Med Biol Res; 1996 Apr; 29(4):473-7. PubMed ID: 8736110
[TBL] [Abstract][Full Text] [Related]
7. Expansion of natural killer (NK) and natural killer-like T (NKT)-cell populations derived from patients with B-chronic lymphocytic leukemia (B-CLL): a potential source for cellular immunotherapy.
Guven H; Gilljam M; Chambers BJ; Ljunggren HG; Christensson B; Kimby E; Dilber MS
Leukemia; 2003 Oct; 17(10):1973-80. PubMed ID: 14513047
[TBL] [Abstract][Full Text] [Related]
8. Progression of natural immunity during one-year treatment of residual disease in neuroblastoma patients with high doses of interleukin-2 after autologous bone marrow transplantation.
Martí F; Pardo N; Peiró M; Bertran E; Amill B; García J; Cubells J; Rueda F
Exp Hematol; 1995 Dec; 23(14):1445-52. PubMed ID: 8542930
[TBL] [Abstract][Full Text] [Related]
9. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
[TBL] [Abstract][Full Text] [Related]
10. Recombinant interleukin 2 enhanced natural killer cell-mediated cytotoxicity in human lymphocyte subpopulations expressing the Leu 7 and Leu 11 antigens.
Lanier LL; Benike CJ; Phillips JH; Engleman EG
J Immunol; 1985 Feb; 134(2):794-801. PubMed ID: 3871216
[TBL] [Abstract][Full Text] [Related]
11. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
Miller JS; Tessmer-Tuck J; Pierson BA; Weisdorf D; McGlave P; Blazar BR; Katsanis E; Verfaillie C; Lebkowski J; Radford J; Burns LJ
Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
[TBL] [Abstract][Full Text] [Related]
12. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
[TBL] [Abstract][Full Text] [Related]
13. Influence of neoadjuvant polychemotherapy on natural killer cell activity in patients with locally advanced cervical squamous carcinoma.
Garzetti GG; Ciavattini A; Provinciali M; Valensise H; Romanini C; Fabris N
Gynecol Oncol; 1994 Jan; 52(1):39-43. PubMed ID: 7508412
[TBL] [Abstract][Full Text] [Related]
14. [Observation on natural killer cell activity in gastric cancer patients and effect of nonspecific immunopotentiator administration on its postoperative reduction].
Oshita H; Saji S; Sugiyama Y; Tanemura H; Sakata K; Tanaka S; Ito T
Nihon Geka Gakkai Zasshi; 1985 Oct; 86(10):1417-25. PubMed ID: 4079897
[TBL] [Abstract][Full Text] [Related]
15. Combined immunogene therapy of IL-6 and IL-15 enhances anti-tumor activity through augmented NK cytotoxicity.
Lin CY; Chuang TF; Liao KW; Huang YJ; Pai CC; Chu RM
Cancer Lett; 2008 Dec; 272(2):285-95. PubMed ID: 18760876
[TBL] [Abstract][Full Text] [Related]
16. Effect of interleukin-12 on antitumor activity of human umbilical cord blood and bone marrow cytotoxic cells.
Condiotti R; Nagler A
Exp Hematol; 1998 Jul; 26(7):571-9. PubMed ID: 9657131
[TBL] [Abstract][Full Text] [Related]
17. Antigenic, functional, and molecular genetic studies of human natural killer cells and cytotoxic T lymphocytes not restricted by the major histocompatibility complex.
Lanier LL; Le AM; Cwirla S; Federspiel N; Phillips JH
Fed Proc; 1986 Nov; 45(12):2823-8. PubMed ID: 3095151
[TBL] [Abstract][Full Text] [Related]
18. Role of cytokines in the adoptive immunotherapy of an experimental model of human head and neck cancer by human IL-2-activated natural killer cells.
Rabinowich H; Vitolo D; Altarac S; Herberman RB; Whiteside TL
J Immunol; 1992 Jul; 149(1):340-9. PubMed ID: 1535088
[TBL] [Abstract][Full Text] [Related]
19. Natural killer and activated killer activities in chronic liver disease and hepatocellular carcinoma: evidence for a decreased lymphokine-induced activity of effector cells.
Hirofuji H; Kakumu S; Fuji A; Ohtani Y; Murase K; Tahara H
Clin Exp Immunol; 1987 May; 68(2):348-56. PubMed ID: 2820634
[TBL] [Abstract][Full Text] [Related]
20. IL-2-driven regulation of NK cell receptors with regard to the distribution of CD16+ and CD16- subpopulations and in vivo influence after haploidentical NK cell infusion.
Huenecke S; Zimmermann SY; Kloess S; Esser R; Brinkmann A; Tramsen L; Koenig M; Erben S; Seidl C; Tonn T; Eggert A; Schramm A; Bader P; Klingebiel T; Lehrnbecher T; Passweg JR; Soerensen J; Schwabe D; Koehl U
J Immunother; 2010; 33(2):200-10. PubMed ID: 20145545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
